nach oben

Drugs

Erschienen in:

01.04.2000 | Review Article

Pharmacoeconomic Considerations in the Management of Hypertension

verfasst von: Dr Helios Pardell, Ricard Tresserras, Pedro Armario, Raquel Hernández del Rey

Erschienen in: Drugs | Sonderheft 2/2000

Einloggen, um Zugang zu erhalten

Abstract

Hypertension is highly prevalent in developed and developing countries (more than 30% of the adult population when a threshold value of 140/90mm Hg is selected). It constitutes one of the major cardiovascular risk factors and accounts for more than 5% of total deaths worldwide.

The economic impact of hypertension is enormous, representing $US23.74 billion in the US in 1995 and approximately $US1685 million in Spain in 1994. Direct costs amount to more than 50% of the total costs of hypertension, and almost 70% of these are attributable to drug treatment. Furthermore, hypertensive patients use medical services 50% more than normotensive individuals, and hypertension represents one of the 3 leading causes of visits to primary healthcare centres.

When considering the cost effectiveness of hypertension treatment, there is no doubt that it is cost effective in comparison with other interventions, although some controversies exist, mainly with respect to mild-to-moderate hypertension and to the long term versus short term benefits. The controversy about the absolute risk of hypertension influences the cost-effectiveness analysis.

Because of the limitations of the available cost-effectiveness analyses, it is currently impossible to recommend the use of any particular antihypertensive drug for all patients with hypertension. Consequently, the choice of antihypertensive in any patient should be guided by clinical experience and the recommendations of the present international guidelines.

Murray CJL, López AD, editors. The global burden of disease. Cambridge, MA: Harvard University Press, 1996

Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N EnglJ Med 1999; 340: 1881–7CrossRef

O’Brien E, Staessen JA. What is ‘hypertension’? Lancet 1999; 353: 1541–3PubMedCrossRef

Hypertension Control. Report of a WHO Expert Committee. WHO Technical Report Series 862. Geneva: World Health Organization, 1996

Pardell H, Armario P, Hernández R, et al. Hypertension. Epidemiology and cost of illness. Dis Manage Health Outcomes 1997; 1: 135–40CrossRef

World Health Organization, International Society of Hypertension. 1999 WHO-ISH guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83

Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571–6CrossRef

Merrill RM, Kessler LG, Udler JM, et al. Comparison of risk estimates for selected diseases and causes of death. Prev Med 1999; 28: 179–93PubMedCrossRef

Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and disatolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598–615PubMedCrossRef

10.

Thorn T. The economic costs of cardiovascular diseases in the United States, 1990. Bethesda, MD: National Heart, Lung and Blood Institute, 1993

11.

Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996; 156: 1926–35CrossRef

12.

Schauffer H, D’ Agostino R, Kannel WB. Risk for cardiovascular disease in the elderly and associated Medicare costs: The Framingham Study. Am J Prev Med 1993; 9: 146–54

13.

Badia X, Rovira J, Tresserras R, et al. The cost of arterial hypertension in Spain. Med Clin (Barc) 1992; 99: 769–73

14.

Pardell H, editor. Phannacoeconomics of arterial hypertension. Madrid: Spanish Society of Hypertension/Spanish League against Arterial Hypertension, 1996

15.

Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment. A review of methodological issues. Health Policy 1991; 19: 55–78CrossRef

16.

Moser M. The cost of treating hypertension. Can we keep it under control without compromising the level of care? Am J Hypertens 1998; 11: 120S–7PubMedCrossRef

17.

Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden: an empirical investigation in primary health care. Scand J Prim Health Care 1991; 9(3): 155–60PubMedCrossRef

18.

Kawachi I, Malcolm LA. Treating mild to moderate hypertension. Cost-effectiveness and policy implications. J Cardiovasc Pharmacol 1990; 16 Suppl. 7: S126–8PubMed

19.

Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–9PubMedCrossRef

20.

Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. Phannacoeconomics 1995; 7: 242–50CrossRef

21.

Mosterd A, D’Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340: 1221–7PubMedCrossRef

22.

National Health Survey, 1995. Madrid: Ministry of Health and Consumer Affairs, 1996

23.

Christiansen T, Pedersen KM, Harvald B, et al. A health economic investigation of the effect of treatment for hypertension. Odense: Odense University Research Report 6, 1987

24.

Ménard J, Cornu PH, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992; 6: 447–58PubMed

25.

Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47–54CrossRef

26.

Prieto M, de Abajo FJ, Montero D, et al. Antihypertensive drugs use in Spain, 1985–1995. Med Clin (Barc) 1998; 110: 247–53

27.

O’Brien B. Patterns of European diagnosis and prescribing. London: Office of Health Economics, 1984

28.

OECD Health Data. Paris: Organization for Economic Cooperation and Development, 1997

29.

The National High Blood Pressure Education program. Bethesda, MD: National Institutes of Health, 1988

30.

Pardell H, Bohigas L. Economic perspective of the health problem of hypertension. In: Consulta SA, editor. International Society of Hypertension. 1988 Hypertension Yearbook. Barcelona: 1989 [Spanish edition]: 1–13

31.

Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Phannacoeconomics 1996; 10: 460–6CrossRef

32.

Russell LB. Cost-effectiveness of antihypertensive treatment. General considerations. Hypertension 1989; 13 (5 Suppl.): 1141–4CrossRef

33.

MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 Suppl. 1: S99–118CrossRef

34.

Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke and coronary heart disease. Pt 2. Effects of short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38PubMedCrossRef

35.

Mancia G, Cattaneo BM, Omboni S, et al. Clinical benefits of a consistent reduction in blood pressure. J Hypertens 1998; 16 Suppl. 6: S35–9

36.

Sytkowski PA, D’Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-tenn treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697–703

37.

MacMahon S, Cutler JA, Stamler J. Antihypertensive drug treatment. Potential, expected, and observed effects on stroke and on coronary heart disease. Hypertension 1989; 13 (5 Suppl.): 145–50CrossRef

38.

Tsevat J, Weinstein MC, Williams LW, et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83: 1194–201PubMedCrossRef

39.

Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 1999; 28: 343–8PubMedCrossRef

40.

Zanchetti A, Mancia G. Editors’ corner: strategies for antihy-pertensive treatment decisions: how to assess benefits? J Hypertens 1997; 15: 215–6PubMed

41.

Madhavan S, Alderman MH. The potential effect of blood pressure reduction on cardiovascular disease. A cautionary note. Arch Intern Med 1981; 141: 1583–6PubMedCrossRef

42.

Ménard J, Chatellier G. Mild hypertension: the mysterious viability of a faulty concept. J Hypertens 1995; 13: 1071–7PubMedCrossRef

43.

Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14: 683–9PubMedCrossRef

44.

MacMahon S. Guidelines for antihypertensive therapy. J Hypertens 1996; 14: 691–3PubMedCrossRef

45.

Zanchetti A, Mancia G. Editors’ corner: benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14: 809–11

46.

Robson J. Information needed to decide about cardiovascular treatment in primary care. BMJ 1997; 314: 277–80PubMedCrossRef

47.

Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary prevention vs secondary prevention. Arch Intern Med 1998; 158: 655–62

48.

Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329–35PubMed

49.

Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47–54CrossRef

50.

Zanchetti A. Cost-effectiveness of antihypertensive therapy: what message to patients and health services? J Hypertens 1998; 16 Suppl. 9: S21–3

51.

Weinstein MC, Stason WB. Hypertension. A policy perspective. Cambridge, MA: Harvard University Press, 1976

52.

Johannesson M, Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992; 1: 250–64PubMedCrossRef

53.

Johannesson M, Borgquist L, Jönsson B, et al. The costs of treating hypertension an analysis of different cut-off points. Health Policy 1991; 18: 141–50PubMedCrossRef

54.

Maynard A. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6: 417–20PubMed

55.

Field K, Thorogood M, Silagy C, et al. Strategies for reducing coronary risk factors in primary care: which is most costeffective? BMJ 1995; 310: 1109–12PubMedCrossRef

56.

UK Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720–6CrossRef

57.

Stason WB. Cost and quality trade-offs in the treatment of hypertension. Hypertension 1989; 13 (5 Suppl.): I145–8PubMedCrossRef

58.

Hilleman DE, Mohiuddin SM, Lucas D, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994; 16: 88–102PubMed

59.

Stason WB. Opportunities for improving the cost-effectiveness of antihypertensive therapy. Am J Med 1986; 81 Suppl. 6C: S45–9CrossRef

60.

Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199–208PubMedCrossRef

61.

Dickerson JEC, Hingorani A, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008–13PubMedCrossRef

62.

Ramsay LE, ul Haq I, Yeo WW, et al. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens Suppl. 1996; 14(5): S187–94PubMed

Titel: Pharmacoeconomic Considerations in the Management of Hypertension
verfasst von: Dr Helios Pardell
Ricard Tresserras
Pedro Armario
Raquel Hernández del Rey
Publikationsdatum: 01.04.2000
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe Sonderheft 2/2000
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200059002-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2000

Pathoaetiology, Epidemiology and Diagnosis of Hypertension

Diuretics as a Basis of Antihypertensive Therapy

Clinical Positioning of Indapamide Sustained Release 1.5mg in Management Protocols for Hypertension

Questions and Answers